Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Active, not recruiting · Phase 2 · NCT05718869
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $112,481
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 26
About the trial
- Sponsor
- City of Hope Medical Center (with National Cancer Institute (NCI))
- Tested
- Biospecimen Collection (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Tafasitamab (biological), Zanubrutinib (drug)
- Dates
- Started 2023-05-18; completion 2027-07-27
- Results posted
- Not yet
This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Giving tafasitamab and zanubrutinib in combination may kill more cancer cells in patients with CLL/SLL than giving either treatment alone.
From ClinicalTrials.gov, last updated 2026-10-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene USA, Inc. reported $112,481 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $112,481
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.